TITLE

Gemtuzumab ozogamicin: A Viewpoint by Alan K. Burnett

AUTHOR(S)
Burnett, A.K.
PUB. DATE
July 2001
SOURCE
Drugs;Jul2001, Vol. 61 Issue 9, p1323
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Deals with the use of monoclonal antibody gemtuzumab ozogamicin as treatment for acute myeloid leukemia. Features of gemtuzumab ozogamicin; Adverse effects.
ACCESSION #
4886160

 

Related Articles

  • Acute Leukemia.  // Current Medical Literature: Leukemia & Lymphoma;2013, Vol. 21 Issue 4, p119 

    A review of the article "Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study," by A. Shah and colleagues, which appeared in the periodical "British Journal of Haematology" in the 2013 issue, is presented.

  • TREATMENT GOAL FOR ACUTE MYELOID LEUKEMIA.  // Clinical Advisor;Sep2010, Vol. 13 Issue 9, p61 

    The article presents an answer to a question related to the treatment goal of a man with acute myeloid leukemia (AML) who also has other health problems.

  • Hematology.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS31 

    Presents an abstract of the research manuscript `High dose Ara-C versus intermediate dose Ara-C as consolidation in adult AML: 5 year follow-up,' by M.K. Gandhi, M. Crump and A. Keating. Acute myelocytic leukemia (AML).

  • Differentiation therapy in acute myelogenous leukemia (non-APL). Waxman, S // Leukemia (08876924);Mar2000, Vol. 14 Issue 3, p491 

    Successful treatment of acute promyelocytic leukemia (APL) has identified several novel approaches to induce leukemic cell differentiation and selective apoptosis by overcoming the site-specific transcriptional repression by dominant fusion leukemogenic proteins characteristic of APL and other...

  • Treatment of relapsed and refractory acute myelogenous leukemia. Estey, E H // Leukemia (08876924);Mar2000, Vol. 14 Issue 3, p476 

    Evidence suggests that the salvage therapy utilized for relapsed and refractory acute myelogenous leukemia (AML) should differ based on the duration of a patient's complete remission (CR), the principal predictor of outcome. While standard regimens have produced higher CR rates than...

  • Antidepressant as Cancer Treatment….  // BioWorld Today;3/19/2012, Vol. 23 Issue 43, Special section p1 

    The article reports that Vesanoid, combined with an antidepressant, can treat some other types of acute myeloid leukemia (AML), according to the British Institute for Cancer Research.

  • Removal of Abnormal Clone of Leukaemic Cells by Splenectomy. Gomez, G.; Hossfeld, D.K.; Sokal, J.E. // British Medical Journal;5/24/1975, Vol. 2 Issue 5968, p421 

    Reports the removal of chronic myelocytic leukemia (CML) by splenectomy. Characteristics of CML; Abnormality in Philadelphia chromosomes; Recurrence of karyotypic abnormalities found in splenic specimen; Application of chemotherapy and immunotherapy.

  • Marlene's story. Paulson, Marlene // Alive;Jul2013, Issue 369, p3 

    A personal narrative is presented which explores the author's experience of being treated for acute myelogenous leukemia at Dr. Castillo's Clinic in Tijuana, New Mexico.

  • New agents for induction and postremission therapy of acute myeloid leukemia. Larson, R A // Leukemia (08876924);Apr2001, Vol. 15 Issue 4, p675 

    Focuses on agents for induction and postremission therapy of acute myeloid leukemia (AML). Agent developed to target a specific enzymatic pathway in AML; Role of oral idarubicin in the development of outpatient anthracycline-based therapies for elderly or refractory patients; Characteristics of...

  • Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Ohnishi, K.; Yoshida, H. // Leukemia (08876924);Apr2002, Vol. 16 Issue 4, p617 

    Studies arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia. Need for careful electrocardiogram monitoring; Analysis of pertinent topics and relevant issues; Implications on the study of leukemia.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics